BRNS — Barinthus Biotherapeutics Share News
0.000.00%
Last trade - 00:00Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing
Brief: Barinthus Bio Announces Strategic Focus In Immunology And Inflammation, Provides A Financial Update
Brief: Barinthus Bio Initiates Phase 1 Clinical Trial Of Vtp-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data From Vtp-300 In Chronic Hepatitis B Virus Infections
Brief: Barinthus Bio Announces Data From Phase 1B/2 Apollo Trial Of Vtp-200 In Persistent HPV Infections
Brief: Barinthus Bio Provides A Financial Update And Announces Anticipated 2024 Corporate Milestones
Brief: Barinthus Biotherapeutics PLC New Partnership Aims To Advance Vaccine Against Mers Coronavirus
Brief: Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Brief: Vaccitech Renames as Barinthus Biotherapeutics
Vaccitech PLC reports results for the quarter ended in June - Earnings Summary
Brief: Vaccitech plc Q2 Net Income USD -23.824 Mln
Vaccitech PLC expected to post a loss of 55 cents a share - Earnings Preview
Brief: Vaccitech To Present Final Data At EASL Congress For Phase 1B/2 HBV002 Study
Brief: Vaccitech Doses First Patient In Prostate Cancer Phase 1/2 Clinical Trial
Brief: Vaccitech Reports First Quarter 2023 Financial Results
Brief: Vaccitech PLC COO Retires